EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study

Carl Blomqvist, Leena Vehmanen, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Johanna Ruohola, Heidi Penttinen, Harri Sievänen, Riku Nikander, Meri Utriainen, Tiina Saarto

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07252-7 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Carl Blomqvist und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Helsinki University Central Hospital, Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Bone Density, Breast Neoplasms, Aromatase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Society of Finland, Finnish Cancer Foundation, Academy of Finland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

We aimed to provide long-term bone mineral density (BMD) data on early breast cancer patients of the BREX (Breast Cancer and Exercise) study. The effects of exercise and adjuvant endocrine treatment 10 years after randomization were analyzed, with special emphasis on aromatase inhibitor (AI) therapy discontinuation at 5 years.

Methods

The BREX study randomized 573 pre- and postmenopausal breast cancer patients into a 1-year supervised exercise program or a control group. 372 patients were included into the current follow-up analysis. BMD (g/cm 2 ) was measured by dual-energy X-ray absorptiometry at lumbar spine (LS), left femoral neck (FN), and the total hip. Separate groups were displayed according to baseline menopausal status, and whether the patient had discontinued AI therapy at 5 years or not.

Results

The BMD change from 5 to 10 years did not significantly differ between the two randomized arms. AI discontinuation at 5 years had statistically significant BMD effects. The FN BMD continued to decrease in patients who discontinued AI therapy during the first 5-year off-treatment, but the decrease was three-fold less than in patients without AI withdrawal (− 1.4% v. − 3.8%). The LS BMD increased (+ 2.6%) in patients with AI withdrawal during the first 5 years following treatment discontinuation, while a BMD decrease (-1.3%) was seen in patients without AI withdrawal.

Conclusion

This study is to our knowledge the first to quantify the long-term impact of AI withdrawal on BMD. Bone loss associated with AI therapy seems partially reversible after stopping treatment. Trial registration: http://www.clinicaltrials.gov/ (Identifier Number NCT00639210).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone DensityBreast NeoplasmsAromatase InhibitorsHumansFemaleMiddle AgedFollow-Up StudiesAdultAgedAbsorptiometry, PhotonPostmenopause

Stichwörter der Autor:innen

Aromatase inhibitor withdrawalBone lossBreast cancer

Substanzen

Aromatase Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, Helsinki University Central Hospital, Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.
  • Department of Oncology, Helsinki University Central Hospital, Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland. leena.vehmanen@hus.fi.
  • Department of Oncology, Faculty of Medicine and Health Technology, Tampere University Hospital, University of Tampere, Tampere, Finland.
  • Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland.
  • Cancer Society of Pirkanmaa, Tampere, Finland.
  • The UKK Institute for Health Promotion Research, Tampere, Finland.

Förderung

  • Cancer Society of Finland
  • Finnish Cancer Foundation
  • Academy of Finland
  • Comprehensive Cancer Center of Helsinki University Central Hospital
  • Kela
  • Finnish Ministry of Education
  • Finska Läkaresällskapet
  • Special Government Grant for Health Science Research

Zitieren

APA

Blomqvist, C., Vehmanen, L., Kellokumpu-Lehtinen, P. L., Huovinen, R., Ruohola, J., Penttinen, H., Sievänen, H., Nikander, R., Utriainen, M., & Saarto, T. (2024). Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07252-7

Vancouver

Blomqvist C, Vehmanen L, Kellokumpu-Lehtinen PL, Huovinen R, Ruohola J, Penttinen H, et al. Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07252-7

BibTeX
@article{Blomqvist2024,
  author = {Blomqvist, Carl and Vehmanen, Leena and Kellokumpu-Lehtinen, Pirkko-Liisa and Huovinen, Riikka and Ruohola, Johanna and Penttinen, Heidi and Sievänen, Harri and Nikander, Riku and Utriainen, Meri and Saarto, Tiina},
  title = {Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07252-7}
}
Kostenlos starten →